{"nctId":"NCT00280566","briefTitle":"Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)","startDateStruct":{"date":"2005-12"},"conditions":["Bipolar Mania","Bipolar Disorder"],"count":584,"armGroups":[{"label":"Ziprasidone","type":"EXPERIMENTAL","interventionNames":["Drug: Ziprasidone Oral Capsule"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Ziprasidone Oral Capsule","otherNames":["Geodon, Zeldox"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nAdults meeting DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) criteria for Bipolar I Disorder (currently with manic or mixed symptoms)\n\nExclusion Criteria:\n\nUltra rapid cyclers and subjects with significant cardiovascular disease including history of QT prolongation and/or congenital long QT syndrome","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Intervention for a Mood Episode During Double Blind Period","description":"Time to Intervention for Mood Episode (TIME) while on randomized drug after at least 8 weeks of symptom reduction on open-label ziprasidone plus mood stabilizer. Mood episode considered to have occurred and subject discontinued if one or more of the following: Investigator (INV) decides discontinuation is in best interest of subject; loss of effect and/or change to treatment regimen (INV judgment); subject hospitalized for disease under study; Mania Rating Scale (MRS) and/or Montgomery-Asberg Rating Scale (MADRS) rating is ≥18 for 2 consecutive visits scheduled no more than 10 days apart.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"172.159","spread":"5.646"},{"groupId":"OG001","value":"143.133","spread":"7.532"}]}]}]},{"type":"SECONDARY","title":"Time to Discontinuation for Any Reason During Double Blind Period 2","description":"Key Secondary endpoint is time to discontinuation for any reason. Profile of patients remaining in the trial over time.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"153.526","spread":"6.454"},{"groupId":"OG001","value":"123.313","spread":"7.524"}]}]}]},{"type":"SECONDARY","title":"Modified Time to Intervention for a Mood Episode (TIME)","description":"Time to intervention for a mood episode or time to discontinuation for treatment related adverse events, or death due to drug, or death due to disease. Mood episode considered to have occurred and subject discontinued if one or more of the following: Investigator (INV) decides discontinuation is in best interest of subject; loss of effect and/or change to treatment regimen (INV judgment); subject hospitalized for disease under study; Mania Rating Scale (MRS) and/or Montgomery-Asberg Rating Scale (MADRS) rating is ≥18 for 2 consecutive visits scheduled no more than 10 days apart.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168.145","spread":"5.857"},{"groupId":"OG001","value":"140.325","spread":"7.627"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mania Rating Scale (MRS) by Visit During Double Blind Period","description":"Period 2 Baseline = last observation in Period 1 to the start of Period 2. MRS is 11-item scale to measure mania; derived from Schedule for Affective Disorders and Schizophrenia-Change Behavior (SADS-CB). Subscales: Manic Syndrome (elevated mood, less need for sleep, excessive energy and activity, grandiosity), Behavior and Ideation (irritability, motor hyperactivity, accelerated speech, racing thoughts, poor judgment), and Impaired Insight. Racing thoughts range=0 to 2 (highest level of abnormal=2); all other items 0 to 5 (highest level of abnormal=5). Higher score = greater abnormality.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"3.0"},{"groupId":"OG001","value":"0.8","spread":"5.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"4.2"},{"groupId":"OG001","value":"-0.1","spread":"4.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"3.7"},{"groupId":"OG001","value":"0.2","spread":"5.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"5.7"},{"groupId":"OG001","value":"0.8","spread":"5.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"4.3"},{"groupId":"OG001","value":"1.2","spread":"8.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"4.3"},{"groupId":"OG001","value":"1.2","spread":"6.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"6.5"},{"groupId":"OG001","value":"0.2","spread":"5.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"5.5"},{"groupId":"OG001","value":"0.3","spread":"4.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression Severity (CGI-S) Score by Visit During Double Blind Period","description":"Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. Clinical Global Impression Severity Score is 7-item scale rates severity of illness from 0=not assessed, 1= normal to 7=most extremely ill.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.7"},{"groupId":"OG001","value":"0.3","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.9"},{"groupId":"OG001","value":"0.2","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.7"},{"groupId":"OG001","value":"0.1","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.8"},{"groupId":"OG001","value":"-0.1","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.9"},{"groupId":"OG001","value":"0.0","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.9"},{"groupId":"OG001","value":"0.0","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.9"},{"groupId":"OG001","value":"-0.2","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.0"},{"groupId":"OG001","value":"-0.2","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression - Improvement (CGI-I) Score by Visit During Double Blind Period","description":"Clinical Global Impression measures 7 items in Global assessment of improvement in patient's condition; 0=not assessed, 1= very much improved to 7= very much worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.2"},{"groupId":"OG001","value":"2.8","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.4"},{"groupId":"OG001","value":"2.6","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.2"},{"groupId":"OG001","value":"2.5","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.4"},{"groupId":"OG001","value":"2.2","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"1.3"},{"groupId":"OG001","value":"2.2","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.4"},{"groupId":"OG001","value":"2.5","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.4"},{"groupId":"OG001","value":"2.1","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"1.3"},{"groupId":"OG001","value":"2.2","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Montgomery-Asberg Rating Scale (MADRS) Score by Visit During Double Blind Period","description":"Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. MADRS is 10-item instrument measuring depression: scales from 0=Normal to 6 = most abnormal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"4.9"},{"groupId":"OG001","value":"2.7","spread":"7.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"7.4"},{"groupId":"OG001","value":"2.7","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"5.3"},{"groupId":"OG001","value":"1.6","spread":"6.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"5.9"},{"groupId":"OG001","value":"0.4","spread":"5.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"5.9"},{"groupId":"OG001","value":"0.6","spread":"5.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"6.3"},{"groupId":"OG001","value":"0.4","spread":"3.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"5.6"},{"groupId":"OG001","value":"-0.2","spread":"4.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"6.4"},{"groupId":"OG001","value":"1.0","spread":"6.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score by Visit During Double Blind Period","description":"Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. Positive and Negative Syndrome Scale Total Score is 30-item scale measuring severity of psychopathology (16 items), positive symptoms (7 items) and negative symptoms (7 items); scale from 1 (absent) to 7 (extreme)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"8.7"},{"groupId":"OG001","value":"1.5","spread":"6.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"8.3"},{"groupId":"OG001","value":"-0.8","spread":"6.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"6.5"},{"groupId":"OG001","value":"0.3","spread":"9.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"7.1"},{"groupId":"OG001","value":"0.7","spread":"8.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"7.4"},{"groupId":"OG001","value":"-1.0","spread":"6.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"8.0"},{"groupId":"OG001","value":"-0.9","spread":"7.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Postive Scale by Visit During Double Blind Period","description":"Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. Positive Scale is 7-items derived from PANSS; 1 (absent), 2 (minimal) to 7 (extreme).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.6"},{"groupId":"OG001","value":"0.1","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.0"},{"groupId":"OG001","value":"-0.2","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.7"},{"groupId":"OG001","value":"0.3","spread":"3.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.8"},{"groupId":"OG001","value":"0.0","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.2"},{"groupId":"OG001","value":"-0.1","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.2"},{"groupId":"OG001","value":"-0.1","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Scale by Visit During Double Blind Period","description":"Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. Negative Scale is 7 items derived from PANSS; scale is 1 (absent) to 7 (extreme).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"3.1"},{"groupId":"OG001","value":"0.4","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"3.2"},{"groupId":"OG001","value":"-0.1","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.5"},{"groupId":"OG001","value":"0.1","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"3.1"},{"groupId":"OG001","value":"0.4","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"2.3"},{"groupId":"OG001","value":"-0.4","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.6"},{"groupId":"OG001","value":"-0.1","spread":"2.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15},"commonTop":["Sedation","Somnolence","Tremor","Insomnia","Dizziness"]}}}